Ann: Outstanding Results Achieved in Second JHC Clinical Trial, page-68

I’m watching every day for a capitulation in the price so I can properly average down. Might be a bet, but I’m backing it all the way in.

Looking at some potential numbers, dm a while back you posted some numbers based on 16% margin. Did that just come from the reported revenue and EBIT? I wonder because margin on SaaS deals is usually 40%++. We’ll obviously have some one-offs manufacturing HeraBEATS, but once they’re in circulation it’s all gravy. So there will be a very different margin for initial roll-outs and ongoing use.